On May 6, the list of Jiangsu Province's 2024 specialized and new small and medium-sized enterprises (the first batch) was announced. After strict selection and review, Difei Medical Technology (Nanjing) Co., Ltd. relied on its focus and breakthroughs in the field of pathogen detection. and innovation, and successfully obtained the 'Specialized, Specialized and New' small and medium-sized enterprise certification!

Dinfectome Inc., announced on Tuesday that its DIFSEQ-200 sequencer gained approval from the Chinese National Medical Products Administration (NMPA) on November 8, 2023

Recently, the DIFSEQ-200 high-throughput gene sequencer produced by Nanjing Difei Medical Equipment Co., Ltd. was approved by the State Food and Drug Administration for marketing.

Recently, Difei Medical collaborated with the team of Zhu Xiaodong, PICU of Xinhua Hospital Affiliated to Shanghai Jiao Tong University, and published 'Pediatric intensive care unit treatment alters the diversity and composition of the gut microbiota and antimicrobial resistance gene expression in critical' in Frontiers in Microbiology (IF=5.200) ill children》.The article comprehensively reveals the community structure of the intestinal flora of children in PICU, and compares the differences in intestinal flora, gene functions, and changes in metabolism-related pathways in children before and after short-term antibiotic treatment.

Recently, the Department of Respiratory and Critical Care Medicine of the China-Japan Friendship Hospital cooperated with Diffei Medical to conduct mNGS detection on the bronchoalveolar lavage fluid of 32 patients with lung transplantation and primary graft dysfunction (PGD) to explore the The role of local microbiota in lung transplant patients complicated with PGD.Studies have shown that there are changes in the lung flora of patients with PGD grade 3, and the imbalance of lung flora is related to lung immunity.The research results have been published in The Journal of Clinical and Transplantation Research.

In January 2024, Diffei Medical took the lead and jointly published a multi-center research paper in the journal Infection (IF=7.5) with the respiratory team of Nanjing Drum Tower Hospital, Eastern Theater Command General Hospital and Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine.The article included a total of 205 clinical samples from 201 patients with suspected lower respiratory tract infections, performed metagenomic next-generation sequencing (mNGS) and conventional pathogenic tests (CMTs) at the same time, and guided the adjustment of CMTs-negative patients based on the mNGS results. treatment options and evaluate their effectiveness.The study aims to explore the application potential of mNGS in diagnosing suspected lower respiratory tract infections and guiding treatment decisions to prove the feasibility of mNGS in actual clinical scenarios.

A few days ago, the Nanjing Science and Technology Bureau announced the 2023 Nanjing Engineering Technology Research Center Certification List.'Nanjing Infection Metagenome Engineering Technology Research Center' built by Difei Medical Technology (Nanjing) Co., Ltd. has been recognized through the procedures of district-level competent department recommendation, expert review, director's office meeting deliberation, and public announcement!

The development of modern science and technology promotes medical progress. Metagenomic next-generation sequencing (mNGS) technology has gradually entered the clinic from the laboratory and into the public eye, playing a key role in the diagnosis of many patients with difficult infections .

Difei Medical Technology (Nanjing) Co., Ltd. is a star enterprise under Nanjing Shihe Gene Biotechnology Co., Ltd.As a pioneer in the field of pathogenic microorganism detection in China, Difei Medical adheres to the corporate mission of 'born from the sense' and aims at 'innovating technology, transforming medical treatment' to create a more professional and clinically suitable testing product line , Escort the health of the public with advanced medical technology and services.